ArticleMicroorganisms2019
Combined Use of the Ab105-2φΔCI Lytic Mutant Phage and Different Antibiotics in Clinical Isolates of Multi-Resistant
Abstract read
In one paragraph
Article in Microorganisms, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Article
- Synergy antibacterial effects of lytic phage vB_AbaA_LLY and levofloxacin against KL2 and KL160 Acinetobacter baumannii.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Engineered bacteriophages for therapeutic and diagnostic applications.Disease models & mechanisms · 2025Review
- Combined Forces Against Bacteria: Phages and Antibiotics.Health science reports · 2025Article
- StudiesAntimicrobial agents and chemotherapy · 2025Article
- Effect of temperate bacteriophage vB_SauS_S1 on the adaptability and pathogenicity of Staphylococcus aureus ST398.BMC microbiology · 2025Article
- Isolation, characterization, and potential application of Acinetobacter baumannii phages against extensively drug-resistant strains.Virus genes · 2024Article
- Synergistic effects of bacteriophage cocktail and antibiotics combinations against extensively drug-resistant Acinetobacter baumannii.BMC infectious diseases · 2024Article
- A review of the fighting Acinetobacter baumannii on three fronts: antibiotics, phages, and nanoparticles.Molecular biology reports · 2024Review
- Characterization of bacteriophage vB_AbaS_SA1 and its synergistic effects with antibiotics against clinical multidrug-resistant Acinetobacter baumannii isolates.Pathogens and disease · 2024Article
- Improving phage therapy by evasion of phage resistance mechanisms.JAC-antimicrobial resistance · 2024Review
- Exploiting phage-antibiotic synergies to disruptMicrobiology spectrum · 2024Article
- Use of Galleria mellonella as an Animal Model for Studying the Antimicrobial Activity of Bacteriophages with Potential Use in Phage Therapy.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Regulation of anti-phage defense mechanisms by using cinnamaldehyde as a quorum sensing inhibitor.Frontiers in microbiology · 2024Article
- Potential Usefulness of Bacteriophages for the Treatment of Multidrug-ResistantThe Malaysian journal of medical sciences : MJMS · 2023Review
- Case report: Analysis of phage therapy failure in a patient with aFrontiers in medicine · 2023Article
- Recent Advances in Phage-Based Therapeutics for Multi-Drug ResistantBioengineering (Basel, Switzerland) · 2022Review
- Bactericidal Synergism between Phage YC#06 and Antibiotics: a Combination Strategy to Target Multidrug-Resistant Acinetobacter baumanniiMicrobiology spectrum · 2022Article
- Phage-antibiotic combination is a superior treatment against Acinetobacter baumannii in a preclinical study.EBioMedicine · 2022Article
- Phage-Antibiotic Therapy as a Promising Strategy to Combat Multidrug-Resistant Infections and to Enhance Antimicrobial Efficiency.Antibiotics (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Lucia BlascoMicrobiology Department-Research Institute Biomedical A Coruña (INIBIC), Hospital A Coruña (CHUAC), University of A Coruña (UDC), 15495 A Coruña, Spain.ORCID 0000-0002-4039-4142
Anton AmbroaMicrobiology Department-Research Institute Biomedical A Coruña (INIBIC), Hospital A Coruña (CHUAC), University of A Coruña (UDC), 15495 A Coruña, Spain.
Maria LopezMicrobiology Department-Research Institute Biomedical A Coruña (INIBIC), Hospital A Coruña (CHUAC), University of A Coruña (UDC), 15495 A Coruña, Spain.
Laura Fernandez-GarciaMicrobiology Department-Research Institute Biomedical A Coruña (INIBIC), Hospital A Coruña (CHUAC), University of A Coruña (UDC), 15495 A Coruña, Spain.ORCID 0000-0002-8531-6105
Ines BleriotMicrobiology Department-Research Institute Biomedical A Coruña (INIBIC), Hospital A Coruña (CHUAC), University of A Coruña (UDC), 15495 A Coruña, Spain.
Rocio TrastoyMicrobiology Department-Research Institute Biomedical A Coruña (INIBIC), Hospital A Coruña (CHUAC), University of A Coruña (UDC), 15495 A Coruña, Spain.ORCID 0000-0003-4580-7126
Jose Ramos-VivasMicrobiology Department-Research Institute Biomedical Valdecilla (IDIVAL), Hospital Marques de Valdecilla, 39008 Santander, Spain.ORCID 0000-0001-8795-519X
Tom CoenyeLaboratory of Pharmaceutical Microbiology, Ghent University, 9000 Gent, Belgium.
Felipe Fernandez-CuencaClinical Unit for Infectious Diseases, Microbiology and Preventive Medicine, Hospital Universitario Virgen Macarena/Department of Microbiology and Medicine, University of Seville/Biomedicine Institute of Seville (IBIS), 41009 Seville, Spain.
Jordi VilaInstitute of Global Health of Barcelona (ISGlobal), Hospital Clínic-Universitat de Barcelona, 170, 08036 Barcelona, Spain.ORCID 0000-0002-8025-3926
Luis Martinez-MartinezUnit of Microbiology, University Hospital Reina Sofía, Department of Microbiology, University of Córdoba, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), 14004 Cordoba, Spain.ORCID 0000-0002-6091-4045
Jesus Rodriguez-BañoClinical Unit for Infectious Diseases, Microbiology and Preventive Medicine, Hospital Universitario Virgen Macarena/Department of Microbiology and Medicine, University of Seville/Biomedicine Institute of Seville (IBIS), 41009 Seville, Spain.
Alvaro PascualClinical Unit for Infectious Diseases, Microbiology and Preventive Medicine, Hospital Universitario Virgen Macarena/Department of Microbiology and Medicine, University of Seville/Biomedicine Institute of Seville (IBIS), 41009 Seville, Spain.
Jose Miguel CisnerosClinical Unit for Infectious Diseases, Microbiology and Preventive Medicine, Hospital Universitario Virgen del Rocío/Department of Microbiology and Medicine, University of Seville/Biomedicine Institute of Seville (IBIS), 41009 Seville, Spain.
Jeronimo PachonClinical Unit for Infectious Diseases, Microbiology and Preventive Medicine, Hospital Universitario Virgen del Rocío/Department of Microbiology and Medicine, University of Seville/Biomedicine Institute of Seville (IBIS), 41009 Seville, Spain.
German BouMicrobiology Department-Research Institute Biomedical A Coruña (INIBIC), Hospital A Coruña (CHUAC), University of A Coruña (UDC), 15495 A Coruña, Spain.
Maria TomasMicrobiology Department-Research Institute Biomedical A Coruña (INIBIC), Hospital A Coruña (CHUAC), University of A Coruña (UDC), 15495 A Coruña, Spain.ORCID 0000-0003-4501-0387
Funding
Instituto de Salud Carlos III Grant PI16/01163 awarded to M. Tomás.
Abstract
Phage therapy is an abandoned antimicrobial therapy that has been resumed in recent years. In this study, we mutated a lysogenic phage from
Indexed as
Acinetobacter baumanniiantibiotic-phage synergymultiresistantmutant lytic phagephage therapy
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.